Cargando…

Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success

Detalles Bibliográficos
Autores principales:	Da Fonseca, Leonardo G., Reig, Maria, Bruix, Jordi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173463/ https://www.ncbi.nlm.nih.gov/pubmed/30333905 http://dx.doi.org/10.18632/oncotarget.26052

Ejemplares similares

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments
por: Reig, Maria, et al.
Publicado: (2017)

Controversies in the management of hepatocellular carcinoma
por: Forner, Alejandro, et al.
Publicado: (2019)

A good laryngeal view does not guarantee perfectly successful tracheal intubation
por: Hwang, Sung Mi
Publicado: (2016)

Resection vs. transplantation for hepatocellular carcinoma: a never ending challenge
por: Ferrer-Fàbrega, Joana, et al.
Publicado: (2023)

Guarantee of Interneships
Publicado: (1913)

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
por: Corominas, Josep, et al.
Publicado: (2021)

Management of hepatocellular carcinoma: An update
por: Bruix, Jordi, et al.
Publicado: (2011)

Does Lack of Vertical Transmission of COVID-19 Guarantee the Health of the Fetus or Neonate in Infected Mothers?
por: Sadeghi, Mohammad Reza
Publicado: (2020)

Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?
por: Piñero, Federico, et al.
Publicado: (2021)

Portal Hypertension may Influence the Registration of Hypointensity of Small Hepatocellular Carcinoma in the Hepatobiliary Phase in Gadoxetic Acid MR
por: Caparroz, Carla, et al.
Publicado: (2022)

The State and the obligation to guarantee maternal and perinatal health
por: Gaitán-Duarte, Hernando
Publicado: (2022)

Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity
por: da Fonseca, Leonardo G., et al.
Publicado: (2021)

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma
por: Rimassa, Lorenza, et al.
Publicado: (2017)

Early Detection of Colorectal Cancer, Is It a Guarantee for the Cure of Cancer?
por: Lee, Kang Young
Publicado: (2012)

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
por: Farfan-Portet, María-Isabel, et al.
Publicado: (2013)

Endoscopic Retrograde Cholangiopancreatography during Pregnancy: Really Guarantee to Safety?
por: Park, Eun Taek
Publicado: (2015)

How Can the Implementation of Ethical Norms Be Guaranteed in Biomedical Studies?
por: Sadeghi, Mohammad Reza
Publicado: (2020)

Could the Convergence of Science and Technology Guarantee Human Health in the Future?
por: Zarrabi, Ali
Publicado: (2023)

The Operator Volume of Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction Does Not Guarantee Its Quality in Korea
por: Yoon, Chang-Hwan
Publicado: (2019)

Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
por: Kudo, Masatoshi
Publicado: (2022)

Universal coverage in an era of privatisation: can we guarantee health for all?
por: Allotey, Pascale, et al.
Publicado: (2012)

China Endeavors to Guarantee the Implementation of the Healthy China Initiative through Legislation
por: Cao, Yan-Lin, et al.
Publicado: (2018)

Pharmacovigilance and Pharmacoepidemiology as a Guarantee of Patient Safety: The Role of the Clinical Pharmacologist
por: Crescioli, Giada, et al.
Publicado: (2022)

Evolution of systemic therapy for advanced-stage hepatocellular carcinoma
por: Hur, Moon Haeng, et al.
Publicado: (2022)

A heterogeneous landscape does not guarantee high crop pollination
por: Samnegård, Ulrika, et al.
Publicado: (2016)

Locoregional therapies for the treatment of locally advanced hepatocellular carcinoma
por: da Motta-Leal-Filho, Joaquim Maurício
Publicado: (2021)

Novel Therapies for Hepatocellular Carcinoma
por: Rimassa, Lorenza
Publicado: (2020)

Guarantees for representatives of the personnel
Publicado: (2016)

Guarantees for representatives of the personnel
Publicado: (2014)

Assume, Guarantee or Repair
por: Frenkel, Hadar, et al.
Publicado: (2020)

Pro-senescence therapy for hepatocellular carcinoma
por: Muehlich, Susanne, et al.
Publicado: (2013)

Diagnosis, Therapy, and Prognosis for Hepatocellular Carcinoma
por: Ren, Zhigang, et al.
Publicado: (2020)

Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—A Multiparametric Prediction
por: Muñoz-Martínez, Sergio, et al.
Publicado: (2023)

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
por: Tutusaus, Anna, et al.
Publicado: (2018)

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models
por: Cucarull, Blanca, et al.
Publicado: (2020)

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2020)

All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy
por: Kudo, Masatoshi
Publicado: (2023)

Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
por: Han, Sojung, et al.
Publicado: (2020)

Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients?
por: Jang, Byoung Kuk
Publicado: (2016)

Hepatocellular Carcinoma: Carcinogenesis, Establishment, Progression, and Therapies
por: Guan, Yong-Song, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p3vhd62i8d9i7rqk4lghrvjf58